These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24214373)

  • 1. The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease.
    He BX; Shi L; Qiu J; Zeng XH; Zhao SJ
    J Clin Pharmacol; 2014 Apr; 54(4):462-7. PubMed ID: 24214373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.
    Lee YJ; Lee MG; Lim LA; Jang SB; Chung JY
    Int J Clin Pharmacol Ther; 2010 Jan; 48(1):36-45. PubMed ID: 20040338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.
    Shin J; Pauly DF; Pacanowski MA; Langaee T; Frye RF; Johnson JA
    Pharmacotherapy; 2011 Oct; 31(10):942-50. PubMed ID: 21950641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
    Hoch M; Hoever P; Theodor R; Dingemanse J
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1235-45. PubMed ID: 23334403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
    Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
    Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
    Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.
    Pasanen MK; Fredrikson H; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2007 Dec; 82(6):726-33. PubMed ID: 17473846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of
    Wang Y; Tian Y; Lv P; Chen L; Luo W; Jing X; Li H; Tan Z; Wang Y; Zhou H; Ouyang DS
    Pharmazie; 2017 Jun; 72(6):365-368. PubMed ID: 29442027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
    Lilja JJ; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1999 Aug; 66(2):118-27. PubMed ID: 10460065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.
    Ulvestad M; Skottheim IB; Jakobsen GS; Bremer S; Molden E; Asberg A; Hjelmesæth J; Andersson TB; Sandbu R; Christensen H
    Clin Pharmacol Ther; 2013 Mar; 93(3):275-82. PubMed ID: 23361102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin.
    Gao Y; Zhang LR; Fu Q
    Eur J Clin Pharmacol; 2008 Sep; 64(9):877-82. PubMed ID: 18528690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of CYP3A4*1G and CYP3A5*3 With the 1-year Outcome of Acute Ischemic Stroke in the Han Chinese Population.
    Li S; Shi CH; Liu XJ; Li YS; Li SH; Song B; Xu YM
    J Stroke Cerebrovasc Dis; 2019 Jul; 28(7):1860-1865. PubMed ID: 31064695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP.
    Mykkänen AJH; Tarkiainen EK; Taskinen S; Neuvonen M; Paile-Hyvärinen M; Lilius TO; Tapaninen T; Klein K; Schwab M; Backman JT; Tornio A; Niemi M
    Clin Pharmacol Ther; 2024 Jun; 115(6):1428-1440. PubMed ID: 38493369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population.
    He BX; Shi L; Qiu J; Tao L; Li R; Yang L; Zhao SJ
    Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):208-13. PubMed ID: 21199372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
    Dostalek M; Sam WJ; Paryani KR; Macwan JS; Gohh RY; Akhlaghi F
    Clin Pharmacokinet; 2012 Sep; 51(9):591-606. PubMed ID: 22775412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS.
    Hermann M; Christensen H; Reubsaet JL
    Anal Bioanal Chem; 2005 Jul; 382(5):1242-9. PubMed ID: 15933849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of itraconazole on the pharmacokinetics of atorvastatin.
    Kantola T; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1998 Jul; 64(1):58-65. PubMed ID: 9695720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
    Keskitalo JE; Zolk O; Fromm MF; Kurkinen KJ; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2009 Aug; 86(2):197-203. PubMed ID: 19474787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite.
    Narwal R; Akhlaghi F; Asberg A; Hermann M; Rosenbaum SE
    Clin Pharmacokinet; 2010 Oct; 49(10):693-702. PubMed ID: 20818835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.